Partner Headlines - MDCO

  1. Earnings Scheduled For February 18, 2015

    Benzinga
  2. Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up

    IBD
  3. Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs

    Benzinga
  4. Benzinga's Top Upgrades

    Benzinga
  5. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  6. What Investors Should Expect From Rockwell Medical's Next FDA ...

    Benzinga
  7. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Tuesday's After-Hours Movers

    Benzinga
  10. The Medicines Company Surges Amid Credit Suisse Upgrade

    Benzinga
  11. US Stock Futures Surge Ahead Of Earnings, ADP Data

    Benzinga
  12. The Medicines Company Announces First Patient Enrollment In Phase ...

    Benzinga
  13. Midday Gainers From October 28: Buffalo Wild Wings, Integrated ...

    Benzinga
  14. Morning Market Movers

    Benzinga
  15. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  16. BACTIVTM Phase 3 SOLO II Trial Results Published In The Journal ...

    Benzinga
  17. Actavis Expands Antibiotics Presence With Durata Buy

    IBD
  18. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  19. Benzinga's Top Downgrades

    Benzinga
  20. Benzinga's Top Downgrades

    Benzinga
  21. Medicines Co.

    IBD
  22. Mid-Afternoon Market Update: Compuware Holds Onto Gains, Clearwire ...

    Benzinga
  23. Stocks Higher In Afternoon; Thor Industires Jumps

    IBD
  24. Mid-Day Market Update: Verint Shares Jump On Upbeat Results; ...

    Benzinga
  25. Medicines Co. Down On Setback In Hospira Patent Case

    IBD
  26. Stocks Hitting 52-Week Lows

    Benzinga
  27. Mid-Morning Market Update: Markets Gain; Ford March Sales Rise ...

    Benzinga
  28. Morning Market Losers

    Benzinga
  29. Benzinga's Top #PreMarket Losers

    Benzinga
  30. Medicines Co. earnings miss

    IBD
  31. Earnings Scheduled For February 19, 2014

    Benzinga
  32. FDA nixes Medicines' drug

    IBD
  33. Mid-Afternoon Market Update: Market Rally Levels Out As Time ...

    Benzinga
  34. Mid-Day Market Update: U.S. Stocks Rise; Orbitz Shares Surge ...

    Benzinga
  35. Medicines Co. Downgraded After FDA Panel Rejects Drug

    IBD
  36. Mid-Morning Market Update: Markets Drop; Comcast To Acquire Time ...

    Benzinga
  37. Stocks Hitting 52-Week Lows

    Benzinga
  38. UPDATE: Credit Suisse Downgrades The Medicines Company Following ...

    Benzinga
  39. Benzinga's Top #PreMarket Losers

    Benzinga
  40. UPDATE: The Medicines Co. Reminds Investors of FDA CRDAC Meeting ...

    Benzinga
  41. Mid-Afternoon Market Update: Red Robin Continues to Rally as ...

    Benzinga
  42. Leaders Hold Near Buy Points Despite Monday Sell-Off

    IBD
  43. Biotech Stocks Back On Top, Led By Biogen, Alexion

    IBD
  44. Scanning Leading Stocks For Earnings Growth In 2014

    IBD
  45. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga
  46. Medicines acquires Rempex

    IBD
  47. Benzinga's M&A Chatter for Wednesday December 4, 2013

    Benzinga
  48. Medicines Co. Acquires Rempex Pharma; Street Applauds

    IBD
  49. US Stock Futures Edge Higher Ahead Of ADP Report

    Benzinga
  50. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  51. A Few Stocks Form Bases, But Have Flaws

    IBD
  52. Strong Pipeline Expected To Drive Growth At Medicines Co.

    IBD
  53. Medicines Co. Mostly Steady After Low-Volume Breakout

    IBD
  54. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  55. Santarus Earnings Should Top 4 Hot Small-Cap Medicals

    IBD
  56. Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga
  57. LinkedIn, Alliance Fiber Lead Q3 Young Gun Earnings

    IBD
  58. Medicines Co. In Late Stages Of Base Formation

    IBD
  59. Medicines Co. sales topped

    IBD
  60. Medicines Co. Reports Mixed Q3 As New Products Await

    IBD
  61. Medicines Co. Sales Beat Estimates As Angiomax Grows

    IBD
  62. UPDATE: Leerink Swann Raises PT on The Medicines Company Following ...

    Benzinga
  63. The Medicines Company, Alnylam Announce Advance Development ...

    Benzinga
  64. The Medicines Company's Publishes Phase III Data from Trials ...

    Benzinga
  65. UPDATE: Bank of America Upgrades Medicines Company on Leverage

    Benzinga
  66. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga
  67. The Medicines Company Announces Proposed Public Offering of 5.5 ...

    Benzinga
  68. The Medicines Company Announces Positive Phase III Trial Results ...

    Benzinga
  69. Questcor Leads Top 5 Small-Cap, Medical Stocks

    IBD
  70. The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

    Benzinga
  71. Medicines Co. Holding On To Its Recent Big Gains

    IBD
  72. Medicines (MDCO) Chairman & CEO Clive Meanwell sells 7,500 Shares

    GuruFocus
  73. Jefferies Reiterates Buy Rating, $34 PT on Partnership with Alnylam ...

    Benzinga
  74. A Peek Into The Market Before The Trading Starts

    Benzinga
  75. The Medicines Company, Alnylam Announce Global Alliance

    Benzinga
  76. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  77. 3D Systems Leads Top 5 Small Caps Despite Stock Slide

    IBD
  78. Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD

    GuruFocus
  79. Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS

    GuruFocus
  80. Medicines (MDCO) President & CFO Glenn Sblendorio sells 125, ...

    GuruFocus
  81. Medicines (MDCO) Chairman & CEO Clive Meanwell sells 2,500 Shares

    GuruFocus
  82. Small Cap Leaders: 3D Systems, IXIA Lead Top 5 Stocks

    IBD
  83. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  84. Medicines (MDCO) President & CFO Glenn Sblendorio sells 25,0 ...

    GuruFocus
  85. 5 Key Stock Moves From JPMorgan Health Care Confab

    IBD
  86. UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, ...

    Benzinga
  87. Eylea Sales Hurt Regeneron

    IBD
  88. Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma ...

    Benzinga
  89. Medtech Stocks Moving As Conference Makes Waves

    IBD
  90. Medtech Stocks Moving As Conference Makes Waves

    IBD
  91. Mid-Day Market Update: Markets Remain Down, The Medicines Company ...

    Benzinga
  92. The Medicines Co. Offers Results of Phase 3 Trial of Cangrelor ...

    Benzinga
  93. Medicines (MDCO) Chairman & CEO Clive Meanwell sells 5,000 Shares

    GuruFocus
  94. Cadence Pharmaceuticals Terminates Option Agreement to Acquire ...

    Benzinga
  95. Medicines Company to Acquire Incline Therapeutics

    Benzinga
  96. Medicines (MDCO) Chairman & CEO Clive Meanwell sells 13,593 Shares

    GuruFocus
  97. Medicines Company Reports Operating Results (10-Q)

    GuruFocus
  98. Medicines (MDCO) Chairman & CEO Clive Meanwell sells 13,600 Shares

    GuruFocus
  99. UPDATE: Jefferies Upgrades The Medicines Company to Buy on Attractive ...

    Benzinga
  100. The Medicines Company Stops Phase 2b Trial of MDCO-2010

    Benzinga
Trading Center